Use of Ziv Aflibercept in Different Retinal Diseases
Last updated on July 2021Recruitment
- Recruitment Status
- Completed
Summary
- Conditions
- Central Retinal Vein Occlusion With Macular Edema
- Type
- Interventional
- Phase
- Phase 1Phase 2
- Design
- Allocation: N/AIntervention Model: Single Group AssignmentIntervention Model Description: Resistant diabetic macular edema,non ischaemic central retinal vein occlusion and myopic choroidal neovascularisationMasking: None (Open Label)Primary Purpose: Treatment
Participation Requirements
- Age
- Between 31 years and 63 years
- Gender
- Both males and females
Description
Intravitreal injection of 1.25 mg of ziv aflibercept was done in different retinal diseases including myopic CVN,resistant diabetic macular edema to previous ranibizumab injection and non ischaemic CRVO .Thorough ophthalmic evaluation was done including BCVA(best corrected visual acuity) ,anterior a...
Intravitreal injection of 1.25 mg of ziv aflibercept was done in different retinal diseases including myopic CVN,resistant diabetic macular edema to previous ranibizumab injection and non ischaemic CRVO .Thorough ophthalmic evaluation was done including BCVA(best corrected visual acuity) ,anterior and posterior segment examination ,fundus fluorescein angiography and OCT(optical coherence tomography) were performed for all patients .Injection was repeated as PRN(pro re nata) method after one month if persistent intraretinal or subretinal fluid was found.
Tracking Information
- NCT #
- NCT04290195
- Collaborators
- Tanta University
- Investigators
- Not Provided
Get Well Soon